[Treatment of metastatic colorectal cancer: an illustration of the changes in the cancer paradigms].
Until the 2000 decade, survival gains in metastatic colorectal cancer were due to the addition of new cytotoxic agents with original mechanism of action: fluorouracile, the oxaliplatin and irinotecan and also the improvements of liver surgery. During the 2000 decade, the treatment improvements are related to monoclonal antibodies, directed either against the EGF receptor or the VEGF receptor. The molecular characterization of the tumor, especially the presence or absence of k-ras mutation guides the use of targeted therapy. Finally, changes in habits represents an underestimated way to reduce the risk of recurrence and clinical trials are undergoing to evaluate the impact of changes in nutrition and physical exercice.